Regeneron is the best possible home for 23andme.
Regeneron has always been the non-consumer 23andMe, sequencing 1M exomes and finding interesting drug targets from it.
For founders building in consumer testing there some easy learnings looking at 23andme.
- if you're a diagnostic, you need repeat customers
- you need to get paired test <> phenotype for the data to be massively valuable (Tempus a good case of this)
- product shipping and creativity is paramount
Regeneron has been the most innovative pharma, time over time, in adopting new genomic technologies, from early genetics, single cell, and even spatial biology.
Can't think of a better home for 23andMe
Was asked abt acq of @23andMe by @regeneron:
You’d be hard pressed to find better home for these data, or an org more likely than $REGN to both respect the privacy+security issues AND maximize likelihood the knowledge will be used to generate insight+novel therapeutics…
@jgreid
We’re collaborating with @truveta, @illumina, and U.S. health systems to create the largest, most-diverse genetic database of electronic health records and linked genetic data to advance scientific innovation and healthcare delivery.
Come get to know team RGC and celebrate a decade of collaboration and exciting genetic discoveries. Sip, snack, and socialize at our #ASHG23 networking event this Friday night at the Marriott Marquis.
We’re excited to share that the RGC-ME Browser is live! The RGC-ME Browser offers allele frequencies, ancestry estimates, constraint metrics, and transcript annotations based upon a catalog of human protein-coding variations from the exome data of ~1M individuals.
At the remarkable speed of today’s innovation, we’re seeing growth in how organizations leverage generative AI and data. Discover more in @databricks and @techreview’s latest global study, where our Chief Data Officer, @jgreid, shares our journey in data and AI transformation.
Today we, along with our collaborators at @UIME_UNAM, @Oxford_NDPH, @AstraZeneca and @Abbvie are proud to share that our analysis of 140K individuals from the Mexico City Prospective Study (MCPS) has been published in @Nature. Explore the details: https://t.co/DfL3YOtkSr
Since our inception, large-scale human genome sequencing has fueled our discovery, and needless to say, we’ve been busy. As we count down to a decade of team RGC, join us in reflecting on our sequencing milestones that helped us amass the world’s most diverse genetic database. 🌎
We're driven by our commitment to enhancing access to genomic data and findings with research communities #AroundTheWorld. Hear from @uk_biobank’s Sir Rory Collins, FRS, FMedSci, on how our long-term collaboration accelerates discoveries to find determinants of disease.
I know that too many people in the LGBTQI+ community are worried and afraid about their future and their safety.
I want to send a message to the entire community – especially to transgender children.
You are loved.
You are heard.
You are understood.
You belong.
Regeneron is hiring a senior principal scientist to be a founding member of a novel research area focusing on endometriosis. Excited to hear about Regeneron's new preclinical research efforts in women's health and uterine/ovarian diseases.https://t.co/btiwa7r0x4
BREAKING: US Supreme Court issues unanimous opinion striking down Amgen’s PCSK9 patent claims and defending scientific innovation, ending nearly 10-year dispute related to Regeneron-invented medicine.
In 2022, our research in underrepresented populations and global collaborations allowed us to further our understanding of human genetics and biology. Championing transparency, we continue in our commitment to share genetic findings and increase access to diverse genomic data.
We’re very proud to share that insitro CEO & Founder @DaphneKoller has been elected to the National Academy of Sciences in recognition of her pioneering contributions to Machine Learning. Congratulations to Daphne and her distinguished peers for this prestigious recognition! #ML
We’ve worked with @uk_biobank to release the OMOP data conversion of the #genomics data resource, broadening access via the OHDSI data model widely used globally for open source data analysis tools.
“What is unequal and has always been unequal and is still unequal about Rosalind Franklin is the credit that she didn’t get in the aftermath of the discovery,” one historian said. https://t.co/I4P1WR3012